News

China’s National Medical Products Administration approved its first domestically-developed nine-valent human papillomavirus ...
The atopic dermatitis market across the seven major markets is forecast to nearly triple in value over the next decade, ...
A sweeping legislative package backed by US President Donald Trump could strip health insurance from more than 16 million ...
Germany’s Formycon has announced that the Brazilian regulatory authority Anvisa has granted marketing authorization for ...
The NHS Business Services Authority (NHSBSA) has published the annual Prescription Cost Analysis (PCA) for 2024/25.
USA-based subsidiary Vividion Therapeutics has taken over full development and commercialization rights for VVD-214, a ...
The European Commission has granted market authorization for Japanese ophthalmic drugmaker Santen Pharmaceutical’s (TYO: 4536 ...
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning to women taking popular medicines ...
Japanese drugmaker Shionogi and US pharma major Eli Lilly were among the big spenders in pharma M&A during May.
Italian drug discovery specialist Axxam and German AI firm Molecular Health have struck a strategic alliance aimed at ...
US clinical-stage biotech Vigil Neuroscience (Nasdaq: VIGL) today announced a disappointing update on the Phase II IGNITE ...
Neuropsychiatric disorders specialist Alto Neuroscience, has entered into an asset purchase agreement with Chase Therapeutics ...